Document is current

Any future updates will be listed below

782-E Preliminary results of an in progress, first-in-human phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors

Crossref DOI link: https://doi.org/10.1136/jitc-2023-SITC2023.0782-E

Published Online: 2023-10-31

Published Print: 2023-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark